Shopping Cart
Remove All
Your shopping cart is currently empty
Bimekizumab is a humanised monoclonal antibody targeting IL17A/IL17F, capable of reducing IL17A/IL17F levels and blocking inflammation-driven osteoblast differentiation. It is applicable for investigating psoriasis and arthritis.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $373 | - | In Stock | |
| 5 mg | $788 | - | In Stock | |
| 10 mg | $1,230 | - | In Stock |
| Description | Bimekizumab is a humanised monoclonal antibody targeting IL17A/IL17F, capable of reducing IL17A/IL17F levels and blocking inflammation-driven osteoblast differentiation. It is applicable for investigating psoriasis and arthritis. |
| In vitro | Methods: Bimekizumab (10 μg/mL, 1 hour) was used to treat human periosteum-derived cells (hPDCs), and the expression of osteogenesis-related genes was analyzed by real-time quantitative PCR. Results: Bimekizumab effectively suppressed the expression of osteogenic genes through dual neutralization of IL-17A and IL-17F.[1] |
| Synonyms | THPTA |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | IL-17a & IL-17f |
| Molecular Weight | 147.24 kDa |
| Cas No. | 1418205-77-2 |
| Color | Transparent |
| Appearance | Liquid |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature,keep away from direct sunlight | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.